NBER WORKING PAPER SERIES

DO MEDICAL MARIJUANA LAWS REDUCE ADDICTIONS AND DEATHS RELATED
TO PAIN KILLERS?
David Powell
Rosalie Liccardo Pacula
Mireille Jacobson
Working Paper 21345
http://www.nber.org/papers/w21345
NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
July 2015

This paper was supported by a grant from the National Institute on Drug Abuse to the RAND Corporation
(R01DA032693). We appreciate helpful comments from participants of the 2013 Addiction Health
Services Annual Meeting, the Drug Policy Research Center Seminar, the Vanderbilt Law School Drug
Policy Roundtable Meeting, and the Conference of the American Society of Health Economists. The
views expressed herein are those of the authors and do not necessarily reflect the views of the National
Bureau of Economic Research.
NBER working papers are circulated for discussion and comment purposes. They have not been peerreviewed or been subject to the review by the NBER Board of Directors that accompanies official
NBER publications.
¬© 2015 by David Powell, Rosalie Liccardo Pacula, and Mireille Jacobson. All rights reserved. Short
sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided
that full credit, including ¬© notice, is given to the source.

Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers?
David Powell, Rosalie Liccardo Pacula, and Mireille Jacobson
NBER Working Paper No. 21345
July 2015, Revised August 2015
JEL No. I12,I28
ABSTRACT
Many medical marijuana patients report using marijuana to alleviate chronic pain from musculoskeletal
problems and other sources. If marijuana is used as a substitute for powerful and addictive pain relievers
in medical marijuana states, a potential overlooked positive impact of medical marijuana laws may
be a reduction in harms associated with opioid pain relievers, a far more addictive and potentially deadly
substance. To assess this issue, we study the impact of medical marijuana laws on problematic opioid
use. We use two measures of problematic use: treatment admissions for opioid pain reliever addiction
from the Treatment Episode Data Set (TEDS) and state-level opioid overdose deaths in the National
Vital Statistics System (NVSS). Using both standard differences-in-differences models as well as
synthetic control models, we find that states permitting medical marijuana dispensaries experience
a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do
not. We find no impact of medical marijuana laws more broadly; the mitigating effect of medical
marijuana laws is specific to states that permit dispensaries. We evaluate potential mechanisms. Our
findings suggest that providing broader access to medical marijuana may have the potential benefit
of reducing abuse of highly addictive painkillers.
David Powell
RAND Corporation
1776 Main St., 4121
Santa Monica, CA 90407
powelld@nber.org
Rosalie Liccardo Pacula
RAND Corporation
1776 Main Street
P.O. Box 2138
Santa Monica, CA 90407-2138
and NBER
pacula@rand.org

Mireille Jacobson
Paul Merage School of Business
University of California, Irvine
Irvine, CA 92697-3195
and The Paul Merage School of Business
and also NBER
jacobson@nber.org

Introduction
Drug overdoses are the leading cause of deaths from injuries in the United States today,
exceeding deaths from suicide, gunshot deaths and motor vehicle accidents (Murphy et al., 2013). In
2010, 16,651 deaths were caused by a prescription opioid overdose, representing nearly 60% of all drug
overdose deaths, and exceeding overdose deaths from heroin and cocaine combined (Jones, Mack and
Paulozzi, 2013). While a modest decline in opioid overdose deaths has occurred since 2012, more than
16,000 lives are lost to prescription opioids even today (NCHS, 2014).
These numbers are the result of a dramatic rise in problems associated with prescription opioid
abuse over the past two decades, both in terms of morbidity and mortality. While the number of fatal
poisonings due to prescription pain medications quadrupled between 1999 and 2010, the distribution of
opioid pain medications also quadrupled during the same period, demonstrating a parallel rise between
the distribution of opioid pain medication and its abuse nationally (CDC, 2011). Treatment admissions
grew at an even faster rate, increasing nearly six-fold between 1999 and 2009 (CDC, 2011b). Opioidrelated ED visits more than doubled from 21.6 per 100,000 in 2004 to 54.9 per 100,000 in 2011, for a
total of 1.24 million emergency department visits involving non-medical use of pharmaceuticals and
pain relievers in 2011 (SAMHSA, 2013a). It is these trends that led the Centers for Disease Control to
deem the misuse of prescription opioids in the United States an ‚Äúepidemic.‚Äù
Agencies at the federal, state and local level have been implementing a variety of strategies to
tackle the problem, including adopting mandatory prescription monitoring programs, pharmacy lock-in
programs, doctor shopping laws, good Samaritan laws, physician exam requirements, and prescriber
education programs (Levi et al, 2013; CDC 2013a). Evidence from the most recent waves of the
National Household Survey on Drug Use and Health (NHSDUH) and the Drug Abuse Warning Network
(DAWN) suggest that some of these policies may have helped slow the increase. According to the most
recent NSDUH survey, self-reported annual prevalence and dependence on pain relievers has leveled off

1

since 2007 and even declined (temporarily) in a few years (e.g., 2011) (SAMHSA, 2013b). Similarly, the
DAWN data show that between 2009 and 2011, opiate-involved ED visits saw no significant increase
even though nonmedical use of all pharmaceuticals rose 15 percent (SAMHSA, 2013a).
The effectiveness of policy approaches to reducing opioid problems has been relatively
understudied. Prescription drug monitoring programs (PDMPs) have received the most serious
attention. The research evaluating this policy, however, is currently inconclusive due in part to different
definitions of the type of PDMP that is deemed ‚Äúeffective‚Äù (Brady et al., 2014; Riefler et al., 2012;
Paulozzi et al., 2011; Paulozzi & Stier, 2010; Reisman et al., 2009; Simeone & Holland, 2006). Even less
well understood is the potential mitigating role medical marijuana laws might have on opioid misuse.
Many reviews find that marijuana is effective medicine for the treatment of chronic pain (Borgelt et al.,
2013; Lynch & Cambell, 2011; Lueng, 2011; Martin-Sanchez et al., 2009). Furthermore, patients often
seek medical marijuana recommendations for severe or chronic pain (Bowles 2012; Nunberg et al.,
2011).1 To the best of our knowledge, only one study, Bachhuber et al. (2014), considers how medical
marijuana laws affect opiate-related harms. That study focuses only on a rare, albeit important,
outcome ‚Äì overdose deaths. It finds that age-adjusted opiate mortality decreased in states that adopted
medical marijuana laws but does not discriminate among the features of medical marijuana laws that
contributed to this relationship.
In this paper, we examine whether medical marijuana laws reduced prescription opioid misuse.
As of June 2015, twenty-four states and the District of Columbia had enacted laws allowing marijuana to
be used for medicinal purposes; over half of which were passed since 2007. Thus, laws liberalizing
marijuana use were adopted over the same period that opiate problems first exploded and then leveled
off. If marijuana is indeed an effective alternative to prescription opioids, then states that provide legal

1

Nunberg et al (2011) studied over 1600 patients seeking medical marijuana recommendations in California in
2006 ‚Äì 10 years after California‚Äôs law passed ‚Äì and finds half of the patients report seeking medical marijuana to
replace prescription opioid medications.

2

access to patients with these symptoms may have helped stem the rise of prescription opiate use and,
most importantly, misuse. Medical marijuana laws, like prescription drug monitoring programs, vary
along numerous dimensions. One feature of these laws ‚Äì an allowance for retail marijuana sales to
qualified patients through dispensaries - is associated with greater access to and use of marijuana
(Pacula et al., 2015; Wen et al., 2015; Choi, 2014; Pacula et al., 2010) as well as the availability of more
potent marijuana (Sevigny et al., 2014). During our sample period, we observe a huge shift in the legal
protection of legal dispensaries, with 18 of the 24 states with medical marijuana now allowing for
dispensaries, most of which have passed since 2007. Thus, while we study the effects of all medical
marijuana laws in some of our analyses, we focus most of our attention on state medical marijuana laws
that legally protect dispensaries.
We examine two measures of prescription opioid problems: treatment admissions for addiction
to pain relievers (1992-2012) and state-level overdose deaths for opioid medications (1999-2013). We
also examine the extent to which state policies influence the distribution of opioid medication (2000‚Äì
2011), so as to better understand whether medical use of marijuana impacted the legal distribution of
opioid analgesics as a possible mechanism for our findings. We first estimate standard differences-indifferences models, exploiting changes in the allowance of medical marijuana dispensaries to test for
differential changes in outcomes. Given concerns that the adopting states may not be similar to all nonadopting states in terms of pre-policy trends, we also implement a synthetic control approach (Abadie
and Gardeazabal (2003); Abadie, Diamond, and Hainmueller (2010); Abadie, Diamond, and Hainmueller
(2014)). We find no evidence that medical marijuana laws (broadly specified) are associated with
reductions in substance abuse or mortality. However, we find strong evidence that medical marijuana
laws legalizing dispensaries reduce substance abuse treatments for opioids. Our estimates imply
reductions in treatment admissions of over 15%, with even larger reductions suggested by synthetic
control estimation. We also find evidence of reductions in opioid-related mortality. Our difference-in-

3

differences estimate implies a 16% reduction in opioid-related mortality while synthetic control
estimates imply even larger effects of 31% upon the adoption of legal medical marijuana dispensaries.
In contrast to prior work (Bachhuber et al. 2014), we find this reduction only in states with dispensaries
and not in the broader group of medical marijuana states.
To explore potential mechanisms through which this policy might be working, we examine the
influence of the medical marijuana policies on state-level opioid distribution. We find little evidence
that states that legally protect medical marijuana dispensaries experience reductions in morphine dose
equivalent amounts of opioids distributed to them. This result suggests that legalized medical
marijuana distribution replaces illegal opioid acquisition and use, which is not reflected in the legal state
supply of opioids.
The rest of this paper is organized as follows. In Section II, we describe the data. Section III
provides graphical descriptions of our data, followed by a discussion of our empirical strategy in Section
IV. The results are presented in Section V. Section VI includes a discussion and concludes.

I.

Data and Measures
Following the literature on opioid-related harm, we use three different measures of opioid use

and abuse to study the relationship between medical marijuana laws and potential harm from opioids:
opioid-related treatment admissions, opiate-related mortality, and the distribution of opioids to states
from the producers of these medications.
First, we use data from the Treatment Episode Data Set (TEDS) to construct the number of
treatment episodes related to abuse of pain relievers for the period 1992-2013. States collect data on
admissions to treatment facilities receiving public funding (federal block grants, state funds,
publicinsurance dollars) even if those facilities also serve privately insured or cash only patients. While
not a census of substance abuse treatments in the United States, as facilities serving exclusively
privately insured or cash-only patients are not reflected in the sampling frame, examination of national

4

spending on substance abuse treatment shows that the public sector (via Medicare, Medicaid or other
federal, state and local grants or subsidies) have consistently paid over 75% of all substance abuse
treatment in the United States since 1998 (Mack et al., 2011). Thus, the TEDS population will capture
meaningful shifts in state-level trends in treatment for opioid abuse. The TEDS lists up to three
substance of abuse for each admission. We categorize ‚Äúnon-prescription methadone‚Äù and ‚Äúother
opiates and synthetics‚Äù2 admissions as related to pain relievers.
A significant fraction of substance abuse treatments are criminal justice referrals (about 21% in
our data), and the TEDS data provide information on which treatments are referred by the criminal
justice system and which are not. We perform our analysis for all pain reliever substance abuse
treatments and also show results for treatments that are not criminal justice referred. We do this
because simultaneous changes to state criminal justice systems may alter the interpretation of our
results. We find stronger evidence and more precise estimates when we exclude criminal justice
referrals, but we find complementary support for reductions in opioid admissions when we include
them.
Our second measure of problematic opioid use is opioid-related deaths. This measure is based
on mortality data from the National Vital Statistics System (NVSS), a census of deaths in the United
States. Opioid related deaths have been the key driver behind prescription drug overdoses for over a
decade (Jones et al, 2013). We code deaths as related to prescription opioid pain relievers using the
ICD-10 external cause of injury codes (X40-X44, X60-64, X85, or Y10-Y14) and drug identification codes
(T40.2-T40.4). We follow the codes used by the CDC to categorize deaths of any intent (unintentional,

2

These include all non-heroin opiates except non-prescription methadone, such as buprenorphine, codeine,
Hydrocodone, hydromorphone, meperidine, morphine, opium, oxycodone, pentazocine, propoxyphene, tramadol,
and any other drug with morphine-like effects.

5

suicide, homicide or undetermined).3 We limit our analysis to 1999-2013 because prior to 1999, the
NVSS used ICD-9 codes for identifying cause of death and opioid-related deaths are difficult to link
across ICD coding systems. We used the restricted geocoded data with state identifiers to link medical
marijuana laws to opioid-related deaths. We aggregate based on state of occurrence and year.
While the first two data sets measure opioid misuse, we are also interested in opioid use (or
general access). Unfortunately, these data are difficult to find at the state-level. However, information
on the supply of opioids by drug type through legitimate medicinal channels, one measure of access to
opioids, is captured and reflected in the Drug Enforcement Administration‚Äôs (DEA) Automation of
Reports and Consolidated Orders System (ARCOS). The Controlled Substance Act of 1970 requires all
manufacturers and distributors to report their transactions and deliveries of all Scheduled II-V
substances to the Attorney General. ARCOS is the system that monitors and records the flows of these
controlled substances as they move from manufacturers to retail distributors at the local level (down to
the street address and zip code). The data include drug purchases across states by a number of specific
business activities, including pharmacies, hospitals, practitioners, mid-level practitioners and teaching
institutions. However, public data are only available aggregated to the state level.
We received these data by quarter, year, drug type, and state for the years 2000-2011 on all
substances. Following prior work, we constructed morphine-equivalent doses of the 8 most commonly
abused opioid analgesics (Paulozzi et al., 2011; Paulozzi and Ryan, 2006): fentanyl, hydrocodone
(Schedule III), hydromorphone, meperidine, methadone distributed through narcotics treatment
programs; methadone distributed through other outlets as an analgesic, morphine, codeine and
oxycodone (as OxyContin as well as in other forms). Total grams distributed per capita were converted
to morphine equivalent doses drawing on standard multipliers used in this literature (Paulozzi, Kilbourne

3

See http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6226a3.htm.

6

and Desai, 2011; Gammaitoni et al., 2003) and aggregated by state and quarter-year. The outcome
variable is morphine-equivalent doses of opioid analgesics.
Information on state medical marijuana laws were obtained via original legal research of state
statutes and regulations as part of a series of projects funded by the National Institute on Drug Abuse
and the Robert Wood Johnston Foundation over the past decade (Chriqui et al., 2002; Pacula, et al.,
2002; Pacula et al., 2014). Not all medical marijuana laws are alike and recent evidence suggests that
an indicator of ‚Äúmedical marijuana law‚Äù adoption does not adequately capture the different features of
these laws that can impact behavior (Sevigny et al., 2014; Pacula et al., 2014 and 2015). Thus, our main
analysis focuses on the crucial determinant of access to marijuana ‚Äì whether the law legally protects
medical marijuana dispensaries, retail shops that sell marijuana to qualified buyers. We also study
effects in states with ‚Äúactive dispensaries,‚Äù i.e., states with legal or illegal dispensaries but not states
that legally protect dispensaries but do not have any in operation. These come from a comprehensive
media search of major newspapers in each state for stories mentioning the operation of a cooperative
or dispensary. Finally, we estimate effects for states with dispensaries that are both legal and active
since these are likely to provide greatest access.

II.

Descriptive Patterns
To set the stage for our empirical analysis, we begin with a visual display of the trends in our

data sources. In Figure 1, we graph the growth in pain reliever substance abuse treatments, opioidrelated mortality, and opioid distribution for the respective available years in the data. We normalize all
trends to 100 in year 2000. We observe the dramatic increases in opioid use and abuse over this time
period in our data. From 2000 to 2012, opioid substance abuse more than quadrupled. Mortality and
distribution more than tripled.
We also graph the normalized trends in pain reliever treatments, marijuana treatments, and
total treatments for the purposes of comparison in Figure 2. While treatment admissions involving pain

7

relievers rose tremendously over this period, this rapid growth has not been matched by treatments for
any other substance.
Figure 3 graphs trends in opiate treatment admissions by year of adoption of dispensaries, both
by the legal date of adoption and the year of the first active dispensary. The listed year of adoption is
the first full year of adoption so a partial effect may be observed in the year ‚Äúprior‚Äù to adoption. We do
not see any clear consistent patterns in terms of adopting states (or states with active dispensaries) and
opioid treatment admissions, although states with active dispensaries have generally lower growth in
admissions than the non-adopting states from 2000 forward. Importantly, differential pre-policy trends
in treatment admissions across adopting and non-adopting states/states with and without active
dispensaries suggest that standard difference in differences methods, which assume parallel trends, may
not be appropriate for our analysis. We will address this in our analysis by estimating synthetic control
models in addition to more standard difference in differences models.
Figure 4 shows the trend in opioid-related deaths from 1999 to 2013 by medical marijuana
dispensary adoption year. Again, we cannot observe any clear differences in trends between nonadopting and adopting (or active) states. Moreover, we see that adopting states appear to be on
different trends from the start of the sample period, motivating our use of methods to account for
differential trends.
We graph trends in amount of morphine equivalent doses of opioid analgesics distributed to a
state by medical marijuana dispensary adoption year in Figure 5. We observe less evidence of dramatic
variation across states in this measure than observed for either of our abuse measures, but again we see
no strong association of the state dispensary policy on opioids prescribed.

III.

Empirical Strategy
The basis of our empirical strategy is to study changes in our measures of opioid misuse in states

adopting medical marijuana laws to those not adopting these laws. We use the timing of adoption of
8

the marijuana policy for identification. We rely on two complementary methods: (1) a difference-indifferences strategy that uses non-adopting states as controls and differential timing of adoption to
estimate the effect and, (2) a synthetic control group strategy that uses a weighted average of all nonadopting states in a ‚Äúdonor pool‚Äù of states as controls, with the weights empirically constructed based
on the values of covariates and pre-adoption values of the outcome variable (described more below).
We adopt the latter approach because of the concern (discussed above) that non-adopting states are
not appropriate controls for medical marijuana states. Specifically, they may violate the parallel trends
assumption central to a valid difference-in-differences research design, as suggested in Figures 3 and 4.
Our first approach, the traditional difference-in-differences framework, compares changes in
outcomes within adopting states to that in non-adopting states. We implement this strategy by
including state fixed effects and year fixed effects in the following exponential specification:

(1)

‚Ä≤
ùë¶ùë†ùë° = ùëíùë•ùëù(ùõºùë† + ùõæùë° + ùëãùë†ùë°
ùõΩ + ùëÄùëÄùêø‚Ä≤ùë†ùë° ùõø)ùúÇùë†ùë°

where ùë¶ùë†ùë° represents one of our outcomes for state s at time t. Although we could estimate a log-linear
specification using ordinary least squares, we follow Silva and Tenreyro (2006), which shows that a loglinear specification imposes a multiplicative error term in y while Poisson estimation of an exponential
relaxes this assumption, allowing both multiplicative and additive error terms. We also control for timevarying state covariates. We include demographic measures that have been shown to be associated
with prescription drug misuse: the percentage of the state population that is male, the percent white,
and the age distribution within the state (CDC, 2011b). In addition, we control for the state
unemployment rate, which might influence access to insurance/ability to pay for prescription drugs, the
state alcohol tax (a potential substitute), and the log of the population. The vector MML represents our
two alternative indicators for state medical marijuana laws: any law and a law allowing marijuana
dispensaries. Table 1 provides descriptive statistics on our covariates and outcomes.

9

Nineteen states had operational prescription drug monitoring program (PDMPs) during 19992005, but by 2011 nearly all the states had a PDMP. Recent studies find little effect of these laws using
similar analytic approaches (Brady et al., 2014; Paulozzi et al., 2011). We instead use in our analyses
three specific measures from LawAtlas indicating how aggressive a state‚Äôs PDMP is in keeping tabs on
opioid prescriptions, namely (1) whether a state had a ‚Äúproactive PDMP‚Äù, requiring that the state
generate and distribute reports to prescribers, dispensers, or law enforcement authorities without being
solicited, (2) ‚Äúmandatory PDMP‚Äù, which requires all health professionals to report their prescribing in
the system, and (3) ‚Äúreal time PDMP,‚Äù which means that the data in the system is updated at least once
a week if not daily, as opposed to being updated quarterly or monthly.4
We will also employ a complementary event study approach to estimate lagged effects while
also testing for pre-existing trends. For this approach, we estimate equation (1) while allowing for
differential effects based on the time relative to adoption. We will include seven indicators per MML
dimension, representing 3 years or more before adoption, 2 years prior to adoption, 1 year prior to
adoption, year of adoption, 1 year after adoption, 2 years after adoption, and 3 or more years after
adoption. As before, we use the first full year of implementation as the year of adoption so it is possible
that we should observe a partial effect in the year prior to adoption. We include these seven indicators
for each dimension and estimate the event studies for medical marijuana laws and dispensaries jointly.
Our second analytic approach uses the synthetic control group method introduced and
developed in Abadie and Gardeazabal (2003); Abadie, Diamond, and Hainmueller (2010); Abadie,
Diamond, and Hainmueller (2014). This approach creates weights for each state in the ‚Äúdonor pool‚Äù and
the weighted average of the outcome variable in the post-period acts as the counterfactual trend that
would have been observed for the adopting state. Fixed effect models are equivalent to de-meaning
the outcome and explanatory variables in each year, assuming that the average in which each state is

4

Data available at: http://lawatlas.org/query?dataset=corey-matt-pmp. Last accessed January 30, 2015

10

given equal weight is an appropriate comparison for the treated states. Synthetic controls models
permit different (non-equal) weights to be used to create a ‚Äúsynthetic control‚Äù which is more similar to
the treated state.

Z1 is a vector containing all covariates and year-by-year values of the outcome variable for the
pre-treated period. Z 0 is a matrix containing the exact same variables for each state in the donor pool.
The synthetic control approach creates weights W using
ÃÇ = argmin ‚Äñùëç1 ‚àí ùëç0‚Ä≤ ùëä‚Äñ
ùëä
ùëä
ùëâ
subject to ùë§ùëó ‚â• 0 for all j and ‚àë ùë§ùëó = 1
ùëó

where W is a matrix composed of weights represented by ùë§ùëó . The state-specific weights are constrained
to be non-negative. The synthetic control approach is designed to find wj for all donor states such that

y0t ÔÇª ÔÉ• w j y jt in the pre-treatment periods. The estimate for each adopting state i can be written as
j

the average outcome in the post-adoption period relative to the outcome of the synthetic control:
(3)

ÔÅ¢ÀÜi ÔÄΩ

1
T ÔÄ≠ T0

ÔÉ¶

ÔÉ• ÔÉßÔÉß y ÔÄ≠ ÔÉ• wÀÜ y

t ÔÄæT0

ÔÉ®

it

j

j

jt

ÔÉ∂
ÔÉ∑
ÔÉ∑
ÔÉ∏

While the synthetic control approach is intended for use when one state adopts a policy, we observe
multiple states during our time period adopting medical marijuana laws. To aggregate the estimates, we
use
(4)

ùõΩÃÇ = argminùõΩ ‚àëùë†,ùë°‚Äñùë¶ùë†ùë° ‚àí ùõΩ(ùëÄùëÄùêøùë†ùë° ) ‚àí ‚àëùëó ùë§ùëóùë°ùë† ùë¶ùëóùë° ‚Äñ

ùëâ

In words, we choose the estimate on the medical marijuana law dummy that minimizes the
mean squared error. The synthetic control approach assumes that some weighted average of states in
the donor pool can act as an appropriate control for the treated state. This assumption is testable both
through visual inspection of the pre-treatment period and through goodness-of-fit measures. V
11

represents a weighting matrix including the inverse of the mean variance in the pre-period such that we
downweight states in which the synthetic control is a poor fit and more heavily-weights states in which
the synthetic control is a good fit. We also weight by population.
For inference, we adopt and extend the placebo test method suggested in Abadie and
Gardeazabal (2003). With one treated state, the idea is to simulate the distribution of estimates under
the null hypothesis that there is no effect. This inference approach is implemented by repeating the
synthetic control approach for each state in the donor pool, assigning the same year of adoption in each
case. The original treated state is assigned to the donor pool. For each state in the donor pool j, we
obtain a placebo estimate for that state, ÔÅ¢ÀÜi j . This approach allows one to simulate the distribution that
would be observed randomly and one can compare the true estimate with these placebo estimates. We
calculate p-values using

(5)

1
ùêΩ+1

‚àëùêΩùëó=1 1(|ùõΩÃÇùëñ | > |ùõΩÃÇùëñùëó |)

With multiple treated states, we calculate our estimates (equation (4)) as above and simulate the
distribution of these estimates. For these simulations, we randomly select a state from the donor pool
and assign it the adoption year of California. We then randomly select another state (without
replacement) and assign it the adoption year of New Mexico. We do this for all adopting states and
obtain a counterfactual estimate of the overall effect. The distribution of these counterfactual
estimates provides us with a p-value, comparing the absolute value of our estimated effect to the
simulated distribution of the absolute value of the placebo effects. Given the large number of possible
combinations, we randomly generate 1000 estimates of the overall effect to simulate the distribution.
In our synthetic control analyses, we first estimate the effect of adoption of any type of medical
marijuana law, including all other states in the donor pool. We subsequently estimate the effect of
adoption of legal medical marijuana dispensaries using the same donor pool (i.e., we do not include

12

medical marijuana states without dispensaries in the donor pool5). The outcome variables for all
synthetic control analyses are expressed per capita.
We will also use the synthetic control approach to study lagged effects in a manner parallel to the
event study estimation discussed above. The case study synthetic control method allows for the
estimate to vary throughout the post-period. It is straightforward to extend equation (4) to allow for
this heterogeneity as well and we will present some results where we estimate effects for first full year
of adoption, second full year of adoption, and third (and after) full year of adoption. The synthetic
control approach should eliminate any pre-trends so we do not present separate estimates for years
prior to adoption. As expected, these pre-adoption year estimates are all statistically insignificant and
close to zero.

IV.

Results

V.A. The Availability of Medical Marijuana on Measures of Opioid Harm
We present our main difference-in-differences estimates for pain reliever treatment admissions
from the TEDS data in Table 2. We find no statistically significant relationship between medical
marijuana laws and pain reliever substance abuse treatments. However, we find statistically significant
effects for medical marijuana laws with dispensaries at the 10% significance level. We estimate an
effect of -0.170 which implies a reduction in substance abuse of 15.6%.6 When we exclude criminal
justice referrals, we estimate an effect of -0.187 (a 17.1% reduction) and we can reject a null effect at
the 5% significance level.
We find little evidence that ‚Äúactive‚Äù dispensaries have any effect on opioid abuse. However, we
find even larger effects when we study active, legal dispensaries, consistent with our hypothesis that we
should expect greater substitution away from opioids towards marijuana in states where access to

5

Given that we are first testing whether medical marijuana laws without dispensaries have effects, these states
are potentially ‚Äútreated.‚Äù
6
The percent reduction is 100*(exp(-.170)-1)%=-15.6%.

13

marijuana is easiest (both legally and practically). The estimates for these states imply reductions of
28% in opioid substance abuse treatment admissions.7
We disaggregate the above results further by studying the effects of medical marijuana laws and
legal dispensaries by year relative to adoption. We present our event study estimates with 95%
confidence intervals in Figure 6. All of the estimates presented are estimated simultaneously. The
estimates for medical marijuana laws are shown in the figure on the left while the dispensary effects are
shown in the figure on the right. We observe that the effect of both medical marijuana laws and
dispensaries grows over time. By the second year after adoption, dispensaries have a statistically
significant effects on opioid substance abuse treatments. We also estimate statistically significant
effects for medical marijuana laws more generally for 3+ years after adoption.
Our event study results provide little evidence that pre-trends are driving our results. However,
Figure 3 shows that the ‚Äúparallel trends‚Äù assumption may not hold in this context so we implement the
synthetic control estimator to further test the robustness of our findings. Each cell in Table 3 represents
the estimate from a separate synthetic control regression. We first study the relationship between any
MML law and treatment admissions for pain medication using synthetic control methods. Because of
the large number of MML adopting states, we present only the overall effects (findings for individual
states are provided in the appendix (see the first column of Table A2). We find little evidence of a
relationship between MML and treatments. When we focus on legal protection of dispensaries, we find
large and statistically significant effects. We estimate an effect of -0.437, corresponding to a 35%
decrease in substance abuse treatment admissions. When we exclude criminal justice referrals, we
estimate a 53% reduction. Consistent with the Table 2 results, we find especially large estimates for
states with legal and active dispensaries.
7

In states that were the first to adopt laws legally protecting medical dispensaries (CO and CA), dispensaries were
already open and active BEFORE the legal protection was provided. In later adopting states, particularly those
adopted after the 2009 Ogden Memo, it took 2-3 years for dispensaries to become active post passage of law
providing legal protection.

14

Next we examine whether medical marijuana laws influenced opioid-related mortality. Given
that our panel only begins in 1999, we lose several states as treated states when we examine adoption
of any medical marijuana law because these states adopted policies prior to 1999. However, when we
look at adoption of an allowance for legal medical dispensaries, we study the same states as before
since these policies were adopted much later.
In Table 4, we present the difference-in-differences results. As before, we observe no
relationship between general medical marijuana laws and opioid-related deaths, but we do find such a
relationship for legal dispensaries. Our estimate of -0.173 in the final column is statistically significant
from 0 at the 1% level and implies a reduction in opioid-related deaths of 16 percent. We estimate even
larger effects for active dispensaries and active, legal dispensaries. The evidence in Table 4 is relatively
consistent that dispensaries reduce opioid-related deaths.
As before, we can estimate lagged effects and test for the importance of confounding trends
through an event study. We present the results of our event study analysis in Figure 7. We find little
evidence of any effects for medical marijuana laws generally. However, we find further supportive
evidence of large mortality effects for dispensaries. By the first year after adoption, we estimate
statistically significant effects. We can reject the null hypothesis of no effect for 2 years post-adoption
and 3+ years after adoption as well.
The trends in Figure 4 suggest that fixed effect regression techniques may not be appropriate in
this context either so we apply the synthetic control approach here as well. Table 5 presents the overall
estimates from the synthetic control model examining the relationship between medical marijuana laws
and the log of per capita opioid-related deaths. As before, we find estimates larger in magnitude when
the synthetic control approach is used to estimate the impact of dispensaries on opioid abuse. For legal
dispensaries, we estimate a significant (at the 10% level) effect of -0.368, which translates to a 31%
reduction in opioid overdoses; the precision increases (p-value of 0.069) when we consider legal plus

15

active dispensaries. Overall, we find strong, consistent evidence that medical marijuana dispensaries
lead to reductions in opioid-related mortality.
V.B. Medical marijuana laws on measures of opioid distribution
While we have found evidence that medical marijuana dispensaries reduce opioid abuse, as
measured by treatment admissions and possibly opioid overdose deaths, we know very little about the
mechanism driving this result. To shed some light on mechanisms, we consider the distribution of
opioid analgesic medications to legal medical markets using the ARCOS data. Table 6 presents the
results for morphine equivalent doses of our 8 primary opioids of abuse pooled together. We estimate
that legal dispensaries reduce opioid distribution to the state by over 4%. We also find that medical
marijuana laws in general are associated with increases in opioid distribution.
Our synthetic control estimates do not confirm either of these relationships, however.
Furthermore, our event study analysis does not suggest any significant effects either. In Figure 8, we
show the corresponding event study graphs. We find no statistical relationships between our timerelative-to-adoption indicators and legal distribution. In Table 7, we present results from our synthetic
control models and find little evidence that medical marijuana laws, even those which legalized
dispensaries, have any effect on the distribution of legal opioids to a state. This result suggests that
medical marijuana laws do not alter legal opioid access, implying that the opioid abuse increases are
resulting from illegal, nonmedical acquisition of opioids.

V.C. Synthetic Control Estimates of Lagged Effects
In Figures 6 and 7, we presented evidence that the impact of legal dispensaries on opioid
treatment admissions and mortality grows in magnitude over time. This trend is consistent with medical
marijuana markets growing over time after legalization and the lagged impact of misuse on treatments

16

and deaths. We further study this source of heterogeneity by disaggregating our synthetic control
results by time relative to adoption. We present estimates for all of our outcomes in Table 8.
In the first column, we show estimates for substance abuse treatments. The estimate does
grow in magnitude over time, though we cannot statistically reject zero when disaggregating the overall
effect in this manner. The mortality effects for dispensaries also grow in magnitude over time relative to
adoption. The effect is largest and statistically significant from zero for 3+ years after adoption. We also
estimates a positive effect for medical marijuana laws more generally, which we did not observe in any
prior analysis. We cannot reject the null hypothesis that medical marijuana laws are not associated with
any differences in legal distribution of opioids.
Consistent with the results in Section V.B., we find little evidence of effects on legal distribution
of opioids (the last column in Table 8). Even 3+ years after adoption, we estimate a small and positive
effect of dispensaries on legal opioid distribution.
V.D. Heterogeneous Effects by Demographics
While more men die annually from drug overdoses, women have experienced a larger increase
in overdose deaths than men since 1999 (CDC, 2013b). Similarly, people ages 18-25 are most likely to
use opioids recreationally, but ‚Äúmiddle age is the most vulnerable time for opioid overdoes‚Äù (Webster et
al., 2011). Consequently, we might expect medical marijuana access to have differential effects on
opioid abuse by sex and age.
We replicate our synthetic control results for legal dispensaries, selecting on age and sex. We
present results for substance abuse treatment admissions and opioid-related mortality in Table 9. In
the case of treatment admissions, we find a robust effect of our legally protected dispensary variable on
both men and women as well as young and old. However, we find stronger effects for women than
men, which would suggest that woman are even more likely than men to switch to marijuana from
opioids. Similarly, we see much stronger effects on treatment admissions for the older group than the

17

younger group, again suggesting that these policies are having the greatest effect on the groups
experiencing the greatest harms from opioid abuse.
However, when we look at the mortality data, we do not see the same patterns. To the
contrary, while we find a negative relationship that is marginally significant between the dispensary
variable and male mortality, we find no relationship at all between this policy and mortality by women,
even though they are the group that has experienced the greatest increase in mortality and our previous
result of a large effect on treatment admissions. The effects across age groups (less than 40 and 40+)
are relatively uniform too, contrary to our findings on treatment admissions.

V.

Discussion

Considerable attention has been paid in the literature to the potential unintended consequences of
medical marijuana laws, with people examining impacts of these policies on youth initiation,
recreational marijuana use and abuse as well as drunk driving (Wen et al., 2015; Choi, 2014; LynneLandsman et al., 2013; Anderson, Hanson and Rees, 2012 & 2013; Pacula et al., 2013). In this paper we
consider a potential unintended benefit of these laws: a reduction in the misuse of prescription opiates.
Our results are intriguing in that we find fairly strong evidence using both difference-indifferences and synthetic control group methods that states providing legal access to marijuana through
dispensaries experience lower treatment admissions for addiction to pain medications. We provide
complementary evidence that dispensary provisions also reduced deaths due to opioid overdoses. Our
estimates are robust to advanced methods that account for differential trends across adopting and nonadopting states. We estimate even larger effects in states that have both legally protected and active
dispensaries, further supportive evidence that legal access to medical marijuana substitute for opioid
use. The mechanism for this remains a bit unclear, however. We see from the ARCOS data that there is
no effect of these dispensaries on the distribution of opioids through medical channels, suggesting that

18

much of this switch may be driven by the behavior of people using opioids illegally. When we look at
treatment admissions data, it appears that women and those over the age of 40 (the two groups for
which opioid related deaths have risen the most) are even more affected than men and youth in terms
of their responsiveness to this policy. However, we see no similar association between these laws and
opioid related mortality by women or differential mortality by age.
These results differ in a few important ways from a prior study showing that medical marijuana
laws are negatively associated with opioid-related mortality (Bachhuber et al., 2014). First, we have
extra years of data (2011-2013) in which to look for mortality effects, with new states adopting policies
during the window of analysis. Second, we account for a unique feature of medical marijuana laws,
dispensaries or retail stores, that has been shown to have a direct impact on marijuana use, particularly
among adults, and is associated with higher potency (THC/CBD) of marijuana (Sevigny et al., 2014). For
many states, policies providing legal protection of dispensaries lagged behind the initial medical
marijuana policy, and hence the lagged effects observed in Buchhuber et al (2014) might in fact simply
reflect the impact of particular states subsequently providing legal protections to dispensaries (see Table
A1 to identify those states). Finally, unlike the prior study, we explicitly test the robustness of our
findings in two important ways. We look for consistency in our findings in another measure of opioid
abuse (treatment admissions) that is less rare, and hence less sensitive to large outliers. We also
consider the influence of pre-policy trend differences in biasing the magnitude of results by using
synthetic cohort methods.
The fact that opioid harms decline in response to medical marijuana dispensaries raises some
interesting questions as to the extent to which marijuana liberalization policies are potentially beneficial
for public health. Marijuana is a far less addictive substance than opiates and the potential for
overdosing is nearly zero (Hall and Pacula, 2003). However, it remains unclear from our current analysis
whether the findings we observe are short term or will persist. In addition, we ultimately need to weigh

19

any potential indirect benefits from medical marijuana dispensary provisions in terms of its implied
reductions in opiate misuse (or other positive outcomes) against any potential negative impacts of these
provisions on other factors, such as drugged driving.

20

References
Abadie, A., Diamond, A., & Hainmueller, J. (2010). Synthetic control methods for comparative case
studies: Estimating the effect of California‚Äôs tobacco control program. Journal of the American Statistical
Association, 105(490).
Abadie, A., Diamond, A., & Hainmueller, J. (2014). Comparative politics and the synthetic control
method. American Journal of Political Science, forthcoming.
Abadie, A., & Gardeazabal, J. (2003). The economic costs of conflict: A case study of the Basque Country.
American Economic Review, 113-132.
Anderson, D. M., Hansen, B., & Rees, D. I. (2013). Medical marijuana laws, traffic fatalities, and alcohol
consumption. Journal of Law and Economics, 56(2), 333-369.
Anderson, D. M., Hansen, B., & Rees, D. I. (2012). Medical marijuana laws and teen marijuana use (No.
6592 [Rev.]). IZA Discussion Papers.
Bachhuber, M.A., Saloner, B., Cunningham, C.O., Barry, C.L. (2014). Medical Cannabis Laws and Opiate
Analgesic Overdose Mortality in the United States, 1999-2010. JAMA Internal Medicine, August 25.
Brady JE, Wunsch H, DiMaggio C, Lang BH, Giglio J and G Li (2014). Prescription Drug Monitoring and
Dispensing of Prescription Opioids. Public Health Reports 129: 139-147.
Borgelt LM, Franson KL, Nussbaum AM Wang GS (2013). The pharmacologic and clinical effects of
medical cannabis. Pharmacotherapy 33: 195-209.
Centers for Disease Control and Prevention, (2013a). Opioids drive continued increase in drug overdose
deaths: Drug overdose deaths increase for 11th consecutive year. [Press Release].
http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html (accessed May 2014).
Centers for Disease Control and Prevention (CDC. "Vital signs: overdoses of prescription opioid pain
relievers and other drugs among women--United States, 1999-2010." MMWR. Morbidity and mortality
weekly report 62.26 (2013b): 537.

Centers for Disease Control and Prevention (2011). Vital Signs: Overdoses of Prescription Opioid Pain
Relievers ‚Äì United States, 1999-2008. Morbidity and Mortality Weekly Report. 60(43): 1487-1492.
Centers for Disease Control and Prevention (CDC. (2009). Overdose deaths involving prescription opioids
among Medicaid enrollees-Washington, 2004-2007. MMWR. Morbidity and Mortality Weekly
report, 58(42), 1171.
Choi, A. (2014, December). The Impact of Medical Marijuana Laws on Marijuana Use and Other Risky
Health Behaviors. In Health & Healthcare in America: From Economics to Policy. Ashecon.

21

Chriqui, JF; Pacula, RL; McBride, DC; Reichmann DA; VanderWaal CJ and Y Terry-McElrath (2002). Illicit
drug policies: Selected laws from the 50 states and the District of Columbia, Berrien Springs, MI:
Andrews University.
DHHS (2013). Addressing prescription drug abuse in the United States: current activities and future
opportunities. Atlanta: Centers for Disease Control and Prevention, 2013 (http://www
.cdc.gov/homeandrecreationalsafety/overdose/hhs_rx_abuse.html).
Finklea K, Bagalman E, Sacco L. Prescription Drug Monitoring Programs. Congressional Research Service,
January 2013. http://www.fas.org/sgp/crs/misc/R42593.pdf (accessed September 2013).
Gammaitoni AR, Fine P, Alvarez N, et al. (2003). Clinical application of opioid equianalgesic data. Clin J
Pain 19:286 ‚Äì97.
Jones CM, Mack KA, Paulozzi LJ. (2013). Pharmaceutical overdose deaths, United States 2010. JAMA 20;
309(7): 657-659.
Levi J, Segal LM, and AF Miller. (2013). Prescription Drug Abuse: Strategies to Stop the Epidemic 2013.
Robert Wood Johnson Foundation Issue Report.
Lynch ME, Cambell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review
of randomized trials. Br J Clin Pharmacol 72: 735-744.
Lynne-Landsman, S. D., Livingston, M. D., & Wagenaar, A. C. (2013). Effects of state medical marijuana
laws on adolescent marijuana use. American Journal of Public Health, 103(8), 1500-1506.
Mark, T. L., Levit, K. R., Vandivort-Warren, R., Buck, J. A., & Coffey, R. M. (2011). Changes in US spending
on mental health and substance abuse treatment, 1986‚Äì2005, and implications for policy. Health
Affairs, 30(2), 284-292.
Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL (2009). Systematic review and metanalysis of
cannabis treatment for chronic pain. Pain Med 10: 1353-1368.
Murphy SL, Xu J and KD Kochanek (2013). ‚ÄúDeaths: Final Data for 2010‚Äù National Vital Statistics Report
Vol. 61, No. 4: 1-118. May 8, 2013
NCHS. Multiple cause-of-death data, 1999‚Äì2013. CDC WONDER online database. 2014. Available
from: http://wonder.cdc.gov/mcd.html.
Nunberg, Helen; Kilmer, Beau; Pacula, Rosalie Liccardo; and Burgdorf, James R. (2011) "An Analysis of
Applicants Presenting to a Medical Marijuana Specialty Practice in California," Journal of Drug Policy
Analysis: Vol. 4: Iss. 1, Article 1. DOI: 10.2202/1941-2851.1017
Pacula RL, Boustead A, and P Hunt (2014). ‚ÄúWords can be deceiving: A review of variation among legally
effective medical marijuana laws in the United States‚Äù Journal of Drug Policy Analysis. ISSN (Online)
1941-2851, ISSN (Print) 2194-6337,DOI: 10.1515/jdpa-2014-0001, May 2014

22

Pacula RL, Chriqui JF, Reichmann DA, & YM Terry-McElrath (2002). State medical marijuana laws:
Understanding the laws and their limitations. Journal of Public Health Policy, 23(4), 413-439.
Pacula RL, Powell D, Heaton P and E Sevigny (2015). ‚ÄúAssessing the Effects of Medical Marijuana Laws
on Marijuana: The Devil is in the Details‚Äù Journal of Public Policy Analysis and Management. E-view
ahead of print at: DOI: 10.1002/pam.21804 .
Paulozzi LJ, Kilbourne EM, Desai HA (2011). Prescription drug monitoring programs and death rates from
drug overdose. Pain Med 12: 747-754.
Pletcher, M. J., Kertesz, S. G., Kohn, M. A., & Gonzales, R. (2008). Trends in opioid prescribing by
race/ethnicity for patients seeking care in US emergency departments. JAMA, 299(1), 70-78.
Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart DC, et al. (2012). Do prescription drug monitoring
programs impact state trends in opioid abuse/misuse? Pain Med 13: 343-342.
Sevigny, E. L., Pacula, R. L., & Heaton, P. (2014). The effects of medical marijuana laws on
potency. International Journal of Drug Policy. 25(2): 308-319.
Silva, J. S., & Tenreyro, S. (2006). The log of gravity. The Review of Economics and Statistics, 88(4), 641658.
Simeone R and L Holland. 2006. An evaluation of prescription drug monitoring programs. Washington:
Department of Justice (US), Office of Justice Programs.
Substance Abuse and Mental Health Services Administration (SAMHSA), Drug Abuse Warning Network,
2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 134760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration,
2013a.
Substance Abuse and Mental Health Services Administration (SAMHSA), Results from the 2012 National
Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No.
(SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013b.
Volkov ND, Frieden TR, Hyde PS and SS Cha (2014). Medication-Assisted Therapies ‚Äì Tackling the
Opioid-Overdose Epidemic. The New England Journal of Medicine 370(22): 2063-2066.
Webster, Lynn R., et al. "An analysis of the root causes for opioid‚Äêrelated overdose deaths in the United
States." Pain Medicine 12.s2 (2011): S26-S35.

Wen, H., Hockenberry, J. M., & Cummings, J. R. (2015). The effect of medical marijuana laws on
adolescent and adult use of marijuana, alcohol, and other substances. Journal of health economics, 42,
64-80.

23

Figures

0

Per Capita Outcomes
Normalized to 100 in 2000
100
200
300
400

500

Figure 1: Opioid Abuse and Distribution Trends

1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012
Year
Opioid‚àíRelated Treatment Admissions
Opioid‚àíRelated Mortality
Opioid Distribution

Notes: Treatment Admissions from TEDS (1992-2012) using only states which report in each year.
Mortality trends from NVSS (1999-2013).
Distribution trends from ARCOS data (2000-2011).

25

0

Per Capita Outcomes
Normalized to 100 in 2000
100
200
300
400

500

Figure 2: Substance Abuse Treatments Trends by Substance

1992

1994

1996

1998

2000

2002
Year

2004

2006

2008

2010

2012

Opioid‚àíRelated Treatment Admissions
Marijuana Treatment Admissions
All Treatment Admissions

Figure 3: Substance Abuse Treatment Admission Trends by Dispensary Adoption Year
Legal Adoption Date
Per Capita Outcomes
Normalized to 100 in 1992
200
400
600
800

800

0

400
0

Per Capita Outcomes
Normalized to 100 in 1992

1200

Date of First Active Dispensary

1992
1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012
Year

1994

1996

1998

2000

2002
Year

2004

2006

2008

2010

Non‚àíAdopters
California (1996)
Colorado (2005)
Michigan/Montana/New Mexico/Oregon/Washington (2009)
Nevada (2010)
Arizona (2012)

Non‚àíAdopters
California (2004)
New Mexico (2008)
Maine/Rhode Island (2010)
Arizona/Colorado/DC/New Jersey (2011)

Notes: Dates in parentheses refer to first full year of medical marijuana dispensaries.

26

2012

Figure 4: Opioid-Related Mortality Trends by Dispensary Adoption Year
Date of First Active Dispensary

1999

2001

2003

2005

2007

2009

2011

100 200 300 400 500 600
0

0

Per Capita Outcomes
Normalized to 100 in 1999

Per Capita Outcomes
Normalized to 100 in 1999
200
400
600
800

Legal Adoption Date

2013

Year

1999

2001

2003

2005

2007

2009

2011

Year

Non‚àíAdopters
California (2004)
New Mexico (2008)
Maine/Rhode Island (2010)
Arizona/Colorado/DC/New Jersey (2011)

Non‚àíAdopters
CO (2005)
NV (2010)
AZ (2012)

CA (1996)
MI/MT/NM/OR/WA (2009)
ME (2011)
DC/NJ/RI/VT (2013)

Notes: Dates in parentheses refer to first full year of medical marijuana dispensaries.

Figure 5: Opioid Distribution by Dispensary Adoption Year
Date of First Active Dispensary
Per Capita Outcomes
Normalized to 100 in 1999
100
200
300
400
0

0

Per Capita Outcomes
Normalized to 100 in 2000
100
200
300
400

Legal Adoption Date

2000

2002

2004

2006
Year

2008

2010

2000

Non‚àíAdopters
California (1996)
Colorado (2005)
Michigan/Montana/New Mexico/Oregon/Washington (2009)
Arizona/Colorado/DC/New Jersey (2011)

2002

2004

2006
Year

2008

2010

Non‚àíAdopters
California (1996)
Colorado (2005)
Michigan/Montana/New Mexico/Oregon/Washington (2009)
Nevada (2010)

Notes: Dates in parentheses refer to first full year of medical marijuana dispensaries.

27

2013

Figure 6: TEDS Event Study Results
Legal Dispensaries

‚àí3 and Before

‚àí.8

‚àí.8

‚àí.6

‚àí.6

Estimated Effect
‚àí.4
‚àí.2

Estimated Effect
‚àí.4
‚àí.2

0

0

.2

.2

MML

‚àí2

‚àí1
0
1
Year Relative to Adoption

2

3+

‚àí3 and Before

‚àí2

‚àí1
0
1
Year Relative to Adoption

Coefficient Estimate
95% Confidence Interval

2

3+

Coefficient Estimate
95% Confidence Interval

Notes: Estimates in both figures are simultaneously estimated. Year 0 represents first full year of adoption
so a partial eÔ¨Äect for the prior year (-1) may be expected.

Figure 7: Mortality Event Study Results
Legal Dispensaries

‚àí3 and Before

‚àí.5

‚àí.5

‚àí.3

‚àí.3

Estimated Effect
‚àí.1 0 .1
.3

Estimated Effect
‚àí.1 0 .1
.3

.5

.5

.7

.7

MML

‚àí2

‚àí1
0
1
Year Relative to Adoption

2

3+

‚àí3 and Before

Coefficient Estimate
95% Confidence Interval

‚àí2

‚àí1
0
1
Year Relative to Adoption

2

3+

Coefficient Estimate
95% Confidence Interval

Notes: Estimates in both figures are simultaneously estimated. Year 0 represents first full year of adoption
so a partial eÔ¨Äect for the prior year (-1) may be expected.

28

Figure 8: Distribution Event Study Results
Legal Dispensaries

‚àí.1

‚àí.1

‚àí.05

‚àí.05

Estimated Effect
0
.05
.1

Estimated Effect
0
.05
.1

.15

.15

.2

.2

MML

‚àí3 and Before

‚àí2

‚àí1
0
1
Year Relative to Adoption

2

3+

‚àí3 and Before

Coefficient Estimate
95% Confidence Interval

‚àí2

‚àí1
0
1
Year Relative to Adoption

2

3+

Coefficient Estimate
95% Confidence Interval

Notes: Estimates in both figures are simultaneously estimated. Year 0 represents first full year of adoption
so a partial eÔ¨Äect for the prior year (-1) may be expected.

29

Tables
Table 1: Summary Statistics
Variable
Pain Reliever Substance Abuse Treatments (per 10,000)
Excluding Criminal Justice Referrals
Opioid-Related Deaths per 100,000
Morphine-Equivalent Opioid Distribution Per Capita
Unemployment Rate
Beer Taxes (cents)
Any PMP Law
Prescriber Responsibility
Real Time
Proactive Responsibility

Mean
4.26
3.35
4.11
0.25
6.1
24.7
42.7%
25.4%
12.7%
4.7%

Notes: All variables refer to state-years in TEDS (1992-2012), except
for mortality (1999-2013) and distribution (2000-2011).

30

Table 2: TEDS Results: Poisson Estimates
Outcome

Opioid Treatment Admissions

MML

-0.043
(0.117)
-0.170*
(0.098)

Legal Dispensaries
Active Dispensaries

Full Sample
-0.045
-0.079
(0.095)
(0.101)

-0.071
(0.108)

Legal and Active
PMP Prescriber Data
PMP Proactive
PMP Real Time
N

0.039
(0.066)
0.015
(0.126)
-0.057
(0.091)
1021

0.023
(0.060)
-0.012
(0.121)
-0.059
(0.086)
1021

-0.319***
(0.090)
0.056
(0.069)
-0.005
(0.125)
-0.045
(0.090)
1021

Excluding Criminal Justice Referrals
-0.063
-0.104
-0.067
(0.114) (0.097)
(0.099)
-0.187**
(0.092)
-0.083
(0.104)
-0.332***
(0.098)
0.013
0.049
0.032
(0.071) (0.063)
(0.074)
-0.087
-0.077
-0.055
(0.141) (0.134)
(0.139)
-0.03
-0.033
-0.017
(0.100) (0.094)
(0.099)
1021
1021
1021

Notes: Significance Levels: *10%, **5%, ***1%. Standard errors in parentheses adjusted
for clustering at state-level. Covariates include age distribution, % male, unemployment
rate, alcohol taxes, log of the population.

Table 3: Synthetic Control Estimates for Treatment Admissions
log(Per Capita Opioid Treatment Admissions)
MML
Legal Dispensaries
Active Dispensaries
Legal and Active

All
-0.235
[0.524]
-0.437
[0.191]
-0.280
[0.486]
-0.500
[0.115]

Non-CJ
-0.375
[0.259]
-0.749***
[0.006]
-0.517
[0.255]
-0.805***
[0.006]

Notes: Significance Levels: *10%, **5%, ***1%. P-values in brackets
calculated using placebo tests. Synthetic controls calculated using pretreatment outcomes for each pre-treatment year and mean of covariates
(age distribution, % male, unemployment rate, alcohol taxes, log of
the population). ‚ÄúDonor pool‚Äù includes states which never adopt any
medical marijuana law. Only states which report in each year of TEDS
(1992-2012) included. Each estimate in the table is derived from a
separate synthetic control regression.
31

Table 4: Mortality Results: Poisson Estimates
Outcome
Opioid-Related Mortality
MML
Legal Dispensaries

0.087
(0.116)
-0.173***
(0.063)

Active Dispensaries

0.163
(0.102)

-0.236***
(0.090)

Legal and Active
PMP Prescriber Data
PMP Proactive
PMP Real Time
N

0.053
(0.106)

-0.057
(0.039)
-0.01
(0.090)
0.003
(0.039)
765

-0.090**
(0.041)
-0.032
(0.107)
0.012
(0.042)
765

-0.178***
(0.064)
-0.054
(0.040)
-0.029
(0.098)
0.006
(0.039)
765

Notes: Significance Levels: *10%, **5%, ***1%. Standard errors in
parentheses adjusted for clustering at state-level. Covariates include
age distribution, % male, unemployment rate, alcohol taxes, log of the
population.

Table 5: Synthetic Control Estimates for Mortality
log(Per Capita Opioid-Related Deaths)
MML
Legal Dispensaries
Active Dispensaries
Legal and Active

0.274*
[0.054]
-0.368*
[0.083]
-0.012
[0.927]
-0.396*
[0.069]

Notes: Significance Levels: *10%, **5%, ***1%. P-values in brackets
calculated using placebo tests. Synthetic controls calculated using pretreatment outcomes for each pre-treatment year and mean of covariates
(age distribution, % male, unemployment rate, alcohol taxes, log of
the population). ‚ÄúDonor pool‚Äù includes states which never adopt any
medical marijuana law. Each estimate in the table is derived from a
separate synthetic control regression.
32

Table 6: ARCOS Results: Poisson Estimates
Outcome
Total Opioid Distribution
MML
Legal Dispensaries

0.053**
(0.027)
-0.047*
(0.027)

Active Dispensaries

0.040
(0.034)

-0.002
(0.036)

Legal and Active
PMP Prescriber Data
PMP Proactive
PMP Real Time
N

0.039
(0.030)

0.092***
(0.024)
0.025
(0.020)
-0.072**
(0.030)
612

0.085***
(0.024)
0.025
(0.020)
-0.071**
(0.030)
612

-0.028
(0.030)
0.089***
(0.024)
0.023
(0.021)
-0.071**
(0.030)
612

Notes: Significance Levels: *10%, **5%, ***1%. Standard errors in
parentheses adjusted for clustering at state-level. Covariates include
age distribution, % male, unemployment rate, alcohol taxes, log of the
population. Outcome variable is translated into morphine equivalent
units.
Table 7: Synthetic Control Estimates for Distribution
log(Per Capita Opioid Distribution)
MML
MML, Dispensaries
Active Dispensaries
Legal Plus Active

-0.027
[0.712]
0.034
[0.747]
0.06
[0.335]
0.043
[0.700]

Notes: Significance Levels: *10%, **5%, ***1%. P-values in brackets
calculated using placebo tests. Synthetic controls calculated using pretreatment outcomes for each pre-treatment year and mean of covariates
(age distribution, % male, unemployment rate, alcohol taxes, log of
the population). ‚ÄúDonor pool‚Äù includes states which never adopt any
medical marijuana law. Each estimate in the table is derived from a
separate synthetic control regression.
33

Table 8: Synthetic Control Event Study Estimates
Deaths
Distribution
Treatments
MML Dispensaries
1st Full Year -0.157
-0.356
[0.611]
[0.164]
2nd Full Year -0.229
-0.511
[0.552]
[0.101]
3+ Years
-0.262
-0.502
[0.531]
[0.155]

MML
Dispensaries
0.15
-0.057
[0.607]
[0.900]
0.179
-0.256
[0.406]
[0.608]
0.443***
-0.641***
[0.001]
[0.001]

MML Dispensaries
0.011
0.066
[0.853]
[0.442]
-0.015
0.078
[0.511]
[0.839]
-0.050
0.037
[0.875]
[0.669]

Notes: Significance Levels: *10%, **5%, ***1%. Pvalues in parentheses generated through placebo tests.

Table 9: Heterogeneity in Dispensary EÔ¨Äect: Synthetic Control Estimates
Sub-Group
Men
Women Under 40
40+
Treatment Admissions
Mortality

-0.281***
[0.002]
-0.345*
[0.065]

-0.794***
[0.001]
-0.086
[0.675]

-0.378*
[0.070]
-0.379*
[0.072]

-0.506***
[0.004]
-0.365*
[0.084]

Notes: Significance Levels: *10%, **5%, ***1%. P-values in brackets
calculated using placebo tests. Synthetic controls calculated using pretreatment outcomes for each pre-treatment year and mean of covariates
(age distribution, % male, unemployment rate, alcohol taxes, log of
the population). ‚ÄúDonor pool‚Äù includes states which never adopt any
medical marijuana law. Each estimate in the table is derived from a
separate synthetic control regression.

34

A

Appendix Tables

Table A1: Summary of Assumptions Regarding Effective Dates for State Medical Marijuana
Laws and Legally Protected Dispensaries (With Open Dates That Apply During our Study Period
1992-2011)

State

Alaska
Arizona
California
Colorado
Connecticut
Delaware
Washington
DC
Hawaii
Illinois
Maine
Maryland
Massachusetts
Michigan
Minnesota
Montana
Nevada
New
Hampshire
New Jersey
New Mexico
New York
Oregon
Rhode Island
Vermont
Washington^^

Medical MJ
Effective
Date

MJ Dispensary
Legally
Protected?
(Date
Dispensaries
Became Legally
Protected)

First Year
MJ
Dispensary
Legally
Protected &
Active

11/3/1998
11/2/2010
11/5/1996
11/7/2000
5/31/2012
5/13/2011
5/21/2010

3/4/1999
11/29/2010
11/6/1996
12/28/2000
10/1/2012
5/13/2011
7/27/2010

No
Yes (11/2/2010)
Yes (10/8/2003)
Yes (6/7/2010)
Yes(10/1/2012)
Yes (5/13/2011)
Yes (7/27/2010)

Dec 2012*
Jan 2004
June 2010
Aug 2014*
**
Apr 2013*

2012
1996
2005+
2014

6/16/2000
8/1/2013
11/2/1999
5/22/2003
11/6/2012
11/4/2008
5/29/2014
11/2/2004
6/14/2001
7/23/2013

6/16/2000
1/1/2014
12/23/1999
10/2/2003
1/1/2013
12/4/2008
5/30/2014
11/2/2004
10/1/2001
7/23/2013

No
Yes(1/1/2014)
Yes(12/4/2009)
Yes(6/1/2014)
Yes(5/24//2013)
No
Yes(5/30/2014)
No
Yes(7/1/2013)
Yes(7/23/2013)

Mar 2011*

2011

1/18/2010
4/3/2007
7/5/2014
12/3/1998
1/3/2006
5/26/2004
11/3/1998

6/1/2010
7/1/2007
7/5/2014
12/3/1998
1/3/2006
7/1/2004
12/3/1998

Yes(7/1/2010)
Yes(7/1/2007)
Yes(7/5/2014)
Yes(8/14/2013)
Yes(6/16/2009)
Yes (6/2/2011)
No

Medical MJ
Enactment
Date

Year MJ
Dispensary
is Known to
be Active

2013

2009

Mar 2015*+

2009
Dec 2009++

Dec 2012*
July 2009

Dec 2012*
July 2009

Mar 2014
Apr 2013*
June 2013*

July 2009
April 2013
June 2013
2009

___________________________________________________________________________
Note: States that adopted medical MJ policies outside of our time period are treated as ‚Äúcontrol states‚Äù, including
MA (2012), IL (2013), New York (2014) and Maryland (2014). In some instances, dispensaries were legally
allowed in subsequent state policies that fell outside of our evaluation window (e.g. Vermont and Oregon). In other
cases, the state policy that passed medical marijuana did not provide immediate legal protection for dispensaries
(as they had to go through a particular process (e.g. DC), or they emerged in subsequent law (e.g. CA). Thus, and
‚ÄúNA‚Äù in the third column indicates that the dispensaries that were permitted by the policy were provided legal
protection outside of our study period.

35

Table A2: State-by-State Dispensary Estimates
TEDS
Mortality Distribution
Arizona n/a
p-value
pre-treated squared error
California
p-value
pre-treated squared error
Colorado
p-value
pre-treated squared error
DC
p-value
pre-treated squared error
Maine
p-value
pre-treated squared error
New Jersey
p-value
pre-treated squared error
New Mexico
p-value
pre-treated squared error
Rhode Island
p-value
pre-treated squared error

-0.505
[0.208]
0.172
-0.123
[0.667]
0.388
n/a
0.981**
[0.042]
8.9
0.235
[0.500]
0.096
-0.788**
[0.042]
2.989
0.207
[0.500]
2.36

-0.198
[0.500]
0.198
-0.514
[0.125]
1.466
-0.076
[0.750]
0.040
0.585
[0.125]
3.730
-0.147
[0.563]
0.314
0.382
[0.250]
8.895
-0.215
[0.406]
0.521
0.188
[0.500]
0.385

-0.113
[0.229]
0.005
-0.240
[0.143]
0.576
0.060
[0.514]
0.001
-0.109
[0.200]
0.153
-0.022
[0.857]
0.006
0.035
[0.743]
0.004
0.098
[0.486]
0.002
-0.086
[0.457]
0.047

Notes: Significance Levels: *10%, **5%, ***1%. P-values in brackets
calculated using placebo tests. Synthetic controls calculated using pretreatment outcomes for each pre-treatment year and mean of covariates
(age distribution, % male, unemployment rate, alcohol taxes, log of
the population). ‚ÄúDonor pool‚Äù includes states which never adopt any
medical marijuana law. Each estimate in the table is derived from a
separate synthetic control regression.

36

